This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Antitrust - Jazz Pharmaceuticals - Blue Cross Blue Shield - litigation alleging pay-for-delay over narcolepsy drug Xyrem (US)

Jazz Pharmaceuticals, Hikma Pharmaceuticals, Amneal Pharmaceuticals, Par Pharmaceuticals and Lupin Pharmaceuticals are accused of delaying entry of a generic version of the narcolepsy drug Xyrem.

To add details to this Case File regarding legal or economic representatives, please contact editors@mlex.com.

Timeline

Parties

Get the inside track, with MLex

With a global network of expert journalists digging deep into the areas of risk that matter to your business and clients—and the highest standards of impartiality—you can have complete trust in MLex to keep you ahead of the regulatory curve.


  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from specialists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

TRY MLEX FREE FOR 14 DAYS

View the parties now

Already a subscriber? Click here to login